Primary Iga Nephropathy clinical trials

Explore recruiting primary iga nephropathy clinical trials.

Recruiting primary iga nephropathy studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Primary Iga Nephropathy trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A multi-center, randomized, double-blind, placebo-controlled, parallel group, phase III study to evaluate the efficacy and safety of LNP023 in primary IgA nephropathy patients

Italy, Netherlands, Belgium, Hungary, Slovenia, Spain +6 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

SABINE - The efficacy and Safety of delayed-release Budesonide in children with primary IgA nephropathy - a multicenter, interventional phase III, randomized, placebo-controlled, double-blind study.

Poland

Therapeutic confirmatory (Phase III) EU CTIS Study details

A multicenter open-label extension study to evaluate the long-term safety and tolerability of zigakibart in adults with primary IgA nephropathy

Belgium, France, Czechia, Croatia, Greece, Germany +2 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Sefaxersen, an Antisense Inhibitor of Complement Factor B, in Patients with Primary IgA Nephropathy at High Risk of Progression

France, Greece, Czechia, Germany, Italy, Spain +1 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A multicenter rollover extension program (REP) to evaluate the long-term safety and tolerability of open label iptacopan in adult participants with primary IgA nephropathy who have completed a Novartis-sponsored iptacopan parent study in IgAN

Hungary, Sweden, Netherlands, Germany, Denmark, Belgium +7 more

Phase III and phase IV (Integrated) EU CTIS Study details

A Phase 3 Multicenter, Randomized, Double-Blind, Placebo Controlled Trial to Evaluate Efficacy and Safety of Mezagitamab (TAK-079) in Study Participants with Primary IgA Nephropathy in Combination with Stable Background Therapy

Spain, Czechia, Austria, Hungary, Germany, Norway +6 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Primary Iga Nephropathy trials by city

Primary Iga Nephropathy in Toronto Primary Iga Nephropathy in Vancouver Primary Iga Nephropathy in Montreal Primary Iga Nephropathy in Calgary Primary Iga Nephropathy in Edmonton Primary Iga Nephropathy in Ottawa Primary Iga Nephropathy in Winnipeg Primary Iga Nephropathy in Quebec City Primary Iga Nephropathy in Hamilton Primary Iga Nephropathy in Kitchener Primary Iga Nephropathy in London Primary Iga Nephropathy in Halifax Primary Iga Nephropathy in New York Primary Iga Nephropathy in Los Angeles Primary Iga Nephropathy in Chicago Primary Iga Nephropathy in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease